Navigation Links
Rigel Advances Asthma Programs: Two Inhaled Drug Candidates Take Aim at Acute and Chronic Lung Disease
Date:5/16/2012

ajority of the cases are considered allergic asthma, for which there is no known cure.  Acute and severe episodes of the disease make up approximately two million Emergency Room visits each year, accounting for 25% of all visits.

R343, Inhaled SYK Inhibitor
In patients with allergic asthma, allergens, such as pollen, trigger the production of immunoglobulin E (IgE) antibodies, which then bind to mast cells (the body's defense system gatekeepers in the lung) and spark a cascade of intracellular signals to mount an immune response resulting in swelling and inflammation of the airways. SYK is a protein tyrosine kinase that plays a pivotal role in IgE receptor signaling in mast cells. Rigel's R343 is designed to bind to the SYK in mast cells and to interrupt the signal from the IgE receptors. R343's ability to inhibit SYK potentially prevents or stops the immune response to the allergen and may be effective in the short and long-term control of allergic asthma.

Rigel expects to initiate a multi-center, multiple-dose, and placebo-controlled study with R343 in approximately 270 asthma patients this summer.

To view Rigel's R343 Asthma Animation, please go to: http://www.rigel.com/rigel/aa.

R256, Inhaled IL13 Signaling /JAK Inhibitor
In patients with severe or chronic asthma, the cells lining the walls of the respiratory airways and lungs experience persistent inflammation and cellular remodeling resulting in scarring (pulmonary fibrosis) if left untreated.   Inhibition of JAK along the IL13 and IL4 signaling pathways, at the primary cellular level of the airways, may reduce or stop the inflammatory cascade associated with bronchospasms, mucus overproduction, cell wall thickening and other symptoms of chronic lung obstruction.  Rigel has conducted preclinical studies with R256 in a variety of models and expects to initiate preclinical development leading to an I
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer
2. Rigels R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study
3. Rigel Announces Initiation of Phase 1 Clinical Trial of R348 for Rheumatoid Arthritis, Psoriasis and Other Immune Disorders
4. Rigels R788 Shows Preclinical Activity in Type 1 Diabetes Model
5. Rigels R788 Slows Progression of Murine Lupus in Preclinical Studies
6. Rigel to Host Conference Call to Discuss Preliminary Phase 2 Study Results of R788 in Lymphoma
7. Rigels R788 Phase 2a Results Published in Arthritis and Rheumatism
8. Rigel Expects R788 Partnership After Phase 2b Clinical Trials Results
9. Shareholder Class Action Filed Against Rigel Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
10. Rigel Commences Phase 2 Trial of R788 in Peripheral T-Cell Lymphomas
11. Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi2 Clinical Trial of R788 in Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 19, 2014 Intarcia Therapeutics, Inc. ... for its lead candidate ITCA 650 (continuous subcutaneous delivery ... baseline HbA1c levels at the 50 th Annual ... Diabetes (EASD). Data from the open-label, phase 3 FREEDOM-HBL ... sugar in patients with poorly controlled type 2 diabetes. ...
(Date:9/19/2014)... September 19, 2014 Reductions in ... many years in people with diabetes type 2 ... term benefits for the kidneys." Australian researchers ... type 2 diabetes leads to persistent reductions in kidney ... The global study has found that, five and ...
(Date:9/18/2014)... 18, 2014  Low T Center endorses the ... Hyattsville, Maryland earlier this ... proper patient population for testosterone therapy (TRT), as ... with TRT. Examining recent claims from studies that TRT ... epidemiological studies do not provide convincing evidence that ...
Breaking Medicine Technology:Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 4ADVANCE-ON Post-trial Observational Study: Blood Pressure Arm and Glucose Arm Results 2ADVANCE-ON Post-trial Observational Study: Blood Pressure Arm and Glucose Arm Results 3Low T Center Endorses The Joint FDA Committee Meeting on Testosterone 2
... DEERFIELD, IL, June 04, 2007,/PRNewswire-FirstCall/ - Cardiome ... US, Inc. ("Astellas") today,announced results from their ... 2. The trial evaluated the efficacy and ... (iv)") for the treatment of patients who ...
... -- ZymoGenetics,Inc. today announced that interim findings were ... in B-cell chronic,lymphocytic leukemia (B-CLL) at the American ... study included intravenous,administration of higher doses than had ... atacicept was well-tolerated and biologically,active at all dose ...
Cached Medicine Technology:Cardiome And Astellas Announce Positive Results From ACT 2 Trial 2Cardiome And Astellas Announce Positive Results From ACT 2 Trial 3Cardiome And Astellas Announce Positive Results From ACT 2 Trial 4Cardiome And Astellas Announce Positive Results From ACT 2 Trial 5Cardiome And Astellas Announce Positive Results From ACT 2 Trial 6ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial,in B-Cell Chronic Lymphocytic Leukemia 2ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial,in B-Cell Chronic Lymphocytic Leukemia 3
(Date:9/20/2014)... (PRWEB) September 20, 2014 The Arizona ... College (MCC) is celebrating National Manufacturing Day by opening ... enhanced machining, processing and additive manufacturing labs will be ... 3, 2014 at MCC’s Southern and Dobson campus (1833 ... in southeast Lot D. , The AzAMI at MCC ...
(Date:9/20/2014)... Nevada (PRWEB) September 20, 2014 ... extremely successful showing at the PAIN Week conference ... Cosmopolitan Hotel and Casino in Las Vegas from ... MarijuanaDoctors.com primarily attended PAIN Week in the hopes ... as a viable and legitimate tool to treat ...
(Date:9/19/2014)... 20, 2014 Consistent premium price ... the Vision Insurance industry in recent years; however, ... of industry margins. From 2009 to 2014, industry ... provide coverage for routine eye exams and other ... contact lens and refractive surgery. According to IBISWorld ...
(Date:9/19/2014)... September 19, 2014 Unbound , an ... families in regions of the Philippines being affected by both ... than 1,060 families evacuated to the nearest public schools while ... heavy rain and gusty winds to portions of the northern ... flooding. Some homes filled with more than 10 feet of ...
(Date:9/19/2014)... York, NY (PRWEB) September 19, 2014 ... PR News at the Platinum PR and Top Places ... Hyatt in New York City. Camino received honorable mentions ... Shoestring Campaign” — for its work elevating Latina voices ... this incredible organization and be a part of its ...
Breaking Medicine News(10 mins):Health News:National Manufacturing Day Open House at Mesa Community College Oct. 3 2Health News:MarijuanaDoctors.com Experiences Unprecedented Support and Growth at Pain Week 2014 2Health News:Vision Insurance in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Vision Insurance in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Vision Insurance in the US Industry Market Research Report from IBISWorld Has Been Updated 4Health News:Double Threat in Philippines Displaces Thousands of Unbound Families 2Health News:Camino Public Relations Honored for Raising Latina Voices in National Health Care, Immigration Debates 2
... (Nasdaq: GTIV ), a leading provider of comprehensive home,health ... conferences hosted by Oppenheimer & Co., Credit Suisse and,Stephens Inc., ... -- 1:20 p.m. to 1:55 p.m. ET, Monday, November ... & Co. 19th Annual Healthcare Conference in New York. ...
... SGP ) said today that it strongly ... Missouri related to reimbursement by,Missouri,s Medicaid program of ... generics subsidiary, was incorrect.,The company said it will ... all applicable laws and regulations governing reimbursement rules ...
... Technologies Corporation (NASDAQ:DVAX) announced today that it plans to report third quarter ... , ... BERKELEY, Calif. (Business Wire EON) October 30, 2008 -- ... the Oppenheimer 19th Annual Healthcare Conference in New York City on November ...
... Breast Cancer Survivors Learn about the Importance of ... SAN DIEGO, Oct. 30 A large number ... part of the "Know Your,L-Dex" awareness campaign activities ... Houston and Dallas., (Photo: http://www.newscom.com/cgi-bin/prnh/20081030/NY43020 ...
... Conference Call Scheduled Wednesday, November 5, 2008 at 11:00 a.m.,ET ... AFAM ), a leading regional provider of home health ... third quarter,2008 ended September 30, 2008 on Wednesday, November 5, ... the results will begin at 11:00 a.m. ET on,November 5, ...
... International,Inc. (Nasdaq: DATA ), a technology and services ... industry, today announced that,it will host a conference call ... 2008 at 4:30 p.m. ET on Thursday, November 6, ... to dial 412-858-4600 a,few minutes before 4:30 p.m. ET. ...
Cached Medicine News:Health News:Gentiva(R) Health Services to Present at November Investment Conferences Hosted by Oppenheimer, Credit Suisse and Stephens 2Health News:Gentiva(R) Health Services to Present at November Investment Conferences Hosted by Oppenheimer, Credit Suisse and Stephens 3Health News:Schering-Plough to Appeal Jury Decision in Missouri Reimbursement Case 2Health News: Dynavax to Report Third Quarter 2008 Financial Results : -- To Present at Oppenheimer's Healthcare Conference -- 2Health News:'Know Your L-Dex(TM)' (Lymphedema Index) Awareness Campaign Attracts Large Numbers of Breast Cancer Survivors at Komen Race for the Cure(R) Events 2Health News:'Know Your L-Dex(TM)' (Lymphedema Index) Awareness Campaign Attracts Large Numbers of Breast Cancer Survivors at Komen Race for the Cure(R) Events 3Health News:Almost Family, Inc. to Report Third Quarter 2008 Financial Results 2Health News:DATATRAK International Management to Host Conference Call on November 6, 2008 to Discuss Third Quarter and Nine Month Operating Results for 2008 2Health News:DATATRAK International Management to Host Conference Call on November 6, 2008 to Discuss Third Quarter and Nine Month Operating Results for 2008 3
Hartman Mosquito forceps, straight, 3.5"....
Straight 20 mm serrated jaws. Ring handle with ratchet lock and dull finish. Overall length 3.9 inches...
Curved 21 mm serrated jaws. Ring handle with ratchet lock and dull finish. Most popular size or model. Overall length 4.7 inches...
Straight 22 mm serrated jaws. Ring handle with ratchet lock and dull finish. Overall length 4.9 inches...
Medicine Products: